Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trifarotene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG known ✓ | P13631 | 20/20 | 1.00 |
| ▸ | RARB | P10826 | 19/20 | 1.00 |
| ▸ | RARA | P10276 | 17/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382411 | 0.99 | RARG (0.98) | RARGRARBRARA | |
| SCHEMBL382843 | 0.96 | RARG (1.00) | RARGRARBRARA | |
| SCHEMBL382479 | 0.95 | RARG (1.00) | RARGRARBRARA | |
| SCHEMBL23440377 | 0.92 | RARG (0.86) | RARGRARBRARA | |
| SCHEMBL27337609 | 0.92 | RARG (0.85) | RARGRARBRARA | |
| SCHEMBL25040467 | 0.91 | RARG (0.84) | RARGRARBRARA | |
| SCHEMBL382029 | 0.91 | RARG (0.83) | RARGRARBRARA | |
| SCHEMBL382609 | 0.90 | RARG (0.82) | RARGRARBRARA | |
| SCHEMBL29763755 | 0.90 | RARG (0.81) | RARGRARBRARA | |
| SCHEMBL382652 | 0.89 | RARG (0.80) | RARGRARBRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104588-A1 | UROLITHIN COMBINATION | AMAZENTIS SA (CH) | 2026-05-21 | — | — | WO | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260053763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY | KYOTO UNIVERSITY (JP) | 2026-02-26 | — | — | US | claimed |
| US-20250339360-A1 | COSMETIC COMPOSITIONS COMPRISING RETINOIDS AND MOISTURIZERS AND METHODS FOR STABLIZING RETINOIDS | ELC MANAGEMENT LLC (US) | 2025-11-06 | — | — | US | claimed |
| EP-4642476-A2 | SELECTIVE INHIBITORS OF C. ACNES HYALURONIDASES | Cedars-Sinai Medical Center (US) | 2025-11-05 | — | — | EP | claimed |
| US-20250304916-A1 | METHODS AND COMPOSITIONS FOR GENERATING VASCULAR LEPTOMENINGEAL CELLS | TRAILHEAD BIOSYSTEMS INC (US) | 2025-10-02 | — | — | US | claimed |
| US-20250288585-A1 | SYNERGISTIC COMPOSITIONS FOR ENHANCED HAIR GROWTH AND METHODS FOR TREATING HAIR LOSS | THE JOHNS HOPKINS UNIVERSITY | 2025-09-18 | — | — | US | claimed |
| WO-2025133218-A1 | PYRAZINE DERIVATIVES FOR THE TREATMENT OF SKIN DISORDERS | PHAMRI NORDEN AB (SE) | 2025-06-26 | — | — | WO | claimed |
| EP-4574171-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY | Kyoto University (JP) | 2025-06-25 | — | — | EP | claimed |
| WO-2025125508-A1 | CORTEXOLONE-17ΑLPHA-PROPIONATE COMBINATIONS FOR TREATING ACNE | CASSIOPEA S.P.A. (IT) | 2025-06-19 | — | — | WO | claimed |
| US-20150148400-A1 | O/W-EMULSION-TYPE TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING A RETINOID | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-05-28 | — | — | US | claimed |
| US-20150125520-A1 | LIPID NANOCAPSULES COMPRISING A RETINOID, NANODISPERSION AND COMPOSITION CONTAINING THE SAME, PROCESS FOR PREPARING THE SAME AND USE THEREOF IN DERMATOLOGY | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-05-07 | — | — | US | claimed |
| US-8470871-B2 | Ligands that modulate RAR receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-06-25 | — | — | US | claimed |
| US-20120282314-A1 | DERMATOLOGICAL/COSMETIC SKIN DEPIGMENTING COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-11-08 | — | — | US | claimed |
| US-20120258996-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-10-11 | — | — | US | claimed |
| US-8227507-B2 | Ligands that modulate RAR receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-07-24 | — | — | US | claimed |
| EP-1831149-B1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2012-01-25 | — | — | EP | claimed |
| US-20100292296-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-11-18 | — | — | US | claimed |
| US-7807708-B2 | Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-10-05 | — | — | US | claimed |
| US-20080015246-A1 | Novel ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015246-A1 | Novel ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | RARB, RARA, RARG | RARG 3/4885RARB 1/4885RARA 2/4885 |
| US-20120258996-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS | RARB, RARA, RARG | RARG 3/4885RARB 1/4885RARA 2/4885 |
| US-20260053763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY | PKD1, RARB, PKD2 | RARG 9/4885RARB 2/4885RARA 4/4885 |
| US-20120282314-A1 | DERMATOLOGICAL/COSMETIC SKIN DEPIGMENTING COMPOSITIONS | TYR, RARA, MITF | RARG 6/4885RARB 5/4885RARA 2/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | RARG 134/4885RARB 70/4885RARA 354/4885 |
| US-20100292296-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS | RARB, RARA, RARG | RARG 3/4885RARB 1/4885RARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.